Beijing GoBroad Hospital

Beijing GoBroad Hospital is a research hospital that specializes in diagnosing and treating complex and severe cases, performing clinical research, and strategically reforming the biomedicine and medical device industries. It provides a public service platform for clinical research in Beijing. We have assembled a group of famous clinical research professionals from China, as well as a full clinical research support team. Building on its clinical research capabilities, the hospital leverages Beijing’s strong foundation in basic research, entrepreneurial firms, and research institutions to establish a high-level ecosystem for medical innovation.

As one of the flagship hospitals of the GoBroad Healthcare Group, which was founded in 2017, Beijing GoBroad Hospital is a pioneer and practitioner of the research hospital pattern. The group’s four main business sectors are the Center for Challenging and Critical Care Medicine, Clinical Research Center, Precision Diagnosis Center, and Data Intelligence Center. The organization has assembled prominent clinical experts with the goal of advancing medical innovation, and they have constructed an integrated platform that facilitates industry and clinical collaboration.

The majority of the staff is dedicated to providing expert assistance for the transition to clinical innovation. The Early Clinical Research Center, Central Laboratory, Imaging Center, Pathology Center, Clinical Pharmacology, Clinical Evaluation Center for Cardiac Safety, Medical and Statistical Teams, and so on are examples of specialized service teams. Since its founding, the firm has grown quickly, amassing a plethora of knowledge from working with hundreds of cutting-edge pharmaceutical companies and carrying out various trials. Additionally, it has given tens of thousands of difficult and critically ill patients fresh hope.

• Leukemia;
• Lymphoma;
• Myeloma:
• Myelodysplastic syndrome (MDS);
• Myelodysplastic/myeloproliferative neoplasms (MDS/MPN);
• Thalassemia;
• Aplastic anemia;
• Paroxysmal nocturnal hemoglobinuria (PNH);
• Thrombocytopenia;
• Blood coagulation disorders;
• Hemophagocytic lymphohistiocytosis;
• X-linked agammaglobulinemia;
• Idiopathic neutropenia;
• Wiskott-Aldrich syndrome (WAS);
• Immunodeficiencies;
• Chronic granulomatous disease;
• Hyperimmunoglobulin M syndrome;
• Hematopoietic disorders;
• Other blood disorders.

The hospital is located in Changping Life Science Park in Beijing, covering an approximate floor area of ​​100,000 square meters. It is planned to have 500 beds, including 100 beds dedicated to early-stage research. Specializing in solid tumors, hematologic tumors, and brain science, the hospital officially opened in July 2023.

Building 1, No.4 Science Park Road, Life Science Park, Changping District, Beijing, China – 102200

Hematology Department 1: General Hematology
Leading specialist, Tong Chun Rong has 30 years of clinical and laboratory experience in hematologic diseases. The department provides various types of diagnosis and treatment for blood diseases, such as:

• leukemia
• lymphoma
• multiple myeloma and other hematologic tumors;
• thalassemia and other anemic diseases;
• thrombocytopenia and other blood clotting disorders.

The department specializes in comprehensive diagnosis, individualized treatment of hematologic diseases, and treatment of hematologic tumors with such methods as:

• chemotherapy
• targeted therapy
• radiation therapy

In addition, the department is involved in developing overall treatment strategies. The medical team adjusts the dosage of drugs based on their metabolism and monitors concentrations, ensuring the safety and efficacy of treatment.

Hematology Department 2: Transplantation

Leading specialist Wu Tong has 30 years of experience in hematopoietic stem cell transplantation. She has successfully performed more than 4,000 allogeneic transplants.
The department team has extensive experience in the application of hematopoietic stem cell transplantation to treat hematopoietic disorders and immunodeficiencies, such as:

• leukemia;
• myelodysplastic syndrome (MDS);
• myelodysplastic/myeloproliferative neoplasms (MDS/MPN);
• lymphoma;
• multiple myeloma;
• aplastic anemia;
• paroxysmal nocturnal hemoglobinuria (PNH);
• hemophagocytic lymphohistiocytosis (familial and Epstein-Barr virus-associated);
• X-linked agammaglobulinemia;
• idiopathic neutropenia;
• Wiskott-Aldrich syndrome (WAS);
• severe combined immunodeficiencies;
• chronic granulomatous disease;
• hyperimmunoglobulin M syndrome;
• pediatric inflammatory bowel disease and other blood disorders.

Division of Hematology 3: Pediatric Lymphoma

Leading specialist Zhang Yong Hong has more than 30 years of clinical experience in pediatric hematologic diseases, particularly in treating lymphoma and leukemia. Zhang Yong Hong is the scientific director of the professional group specializing in lymphoma at Beijing Children’s Hospital and the founding director of China-Net Children’s Lymphoma.

The department diagnoses and treats various types of lymphomas, including lymphoblastic lymphoma, Burkitt’s lymphoma, anaplastic large-cell lymphoma, and Hodgkin’s lymphoma. The diagnosis and treatment process involves advanced programs that take into account the different types of pathologies, risk factors, and the results of stepwise evaluation during therapy. Treatment is continuously adjusted according to the results obtained. The 5-year complication-free survival rate for all types of non-Hodgkin’s lymphoma is more than 80% and more than 90% for Hodgkin’s lymphoma.

Hematology Department 4: Adult Lymphoma

Ke Xiao Yan, a renowned lymphoma specialist, heads the department. The department employs a second-generation treatment program, integrating patients’ clinical parameters for more accurate prognosis and drug selection.

The department team is exploring new treatment strategies for patients with refractory lymphoma. When relapse occurs after individualized therapy, patients are given an additional course of treatment with 75% efficacy. For patients with relapsed lymphoma or myeloma affecting the central nervous system, individualized treatment is used with 88.9% efficacy.

The medical team creates an individualized treatment plan based on an accurate diagnosis, including targeted therapy, high-dose chemotherapy, and hematopoietic stem cell transplantation.

Medical Laboratory

The medical laboratory covers an area of approximately 5,000 square meters and receives investments of more than 100 million yuan. The laboratory has a team of leading experts from various disciplines with doctoral and master’s degrees. The laboratory specializes in conducting a wide range of clinical tests, such as:

• routine clinical tests;
• cell morphology;
• cytochemistry;
• histopathology and immunohistochemistry;
• flow cytometry analysis;
• fluorescence in situ hybridization (FISH);
• genetic analysis (including genetic analyses of hematologic tumors, genetic blood diseases, and genetic predispositions to blood diseases, genetic analysis of drug metabolism, pathogenic genes, and others);
• analysis of pathogens, drug concentrations, and cytokines.

These tests help physicians provide more accurate and individualized treatment, increasing efficacy, reducing side effects, and eliminating pain syndromes. The medical laboratory also collects, separates, and cryopreserves blood cell components and hematopoietic stem cells.

Pathoanatolical Department 
Dr. Guo Li Gai heads the department and specializes in the pathology of the lymphatic and hematopoietic systems (molecular pathology). He has extensive experience in diagnosing diseases, particularly leukemia, myelodysplastic syndrome (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Since 2006, the doctor has published over 20,000 bone marrow biopsy reports. Since 2014, Guo Li Gai has studied thousands of clinical lymphoma cases and has accumulated rich experience diagnosing hematologic diseases and lymphomas.

To make accurate diagnoses, the pathology department has established a stereoscopic integrated diagnostic model (MICM), which includes morphology (M), immunology (I), cytogenetics (C), and molecular science (M). The department works closely with the Mayo Clinic.